This webinar covers
To conclude this landscape review series, you are invited to a complimentary webinar with the Beacon DDR team where they will be providing additional analysis on the reports and offering an opportunity to ask any questions about the data.
This webinar will uncover further analysis of:
- The Clinical Trial Landscape – A 2022 recap and the key developments made over the past year, top disease indications, non-PARP targets and combination trials.
- The Drug Landscape – The current drug landscape with a focus on PARP1-selective and cell cycle checkpoint assets, repair pathways, targets and more.
We look forward to seeing you there.
Speak with our team about Beacon DDR
What is Beacon DDR?
Beacon DNA Damage Response (DDR) covers trial and drug records for clinical, preclinical, approved and discontinued therapeutics targeting key points in DNA damage response pathways.
This module identifies drugs utilizing the concept of synthetic lethality, and covers DDR repair pathway components, including:
- Damage Sensors
- Signalling/Mediator Proteins
- Effector Proteins
- Cell Cycle Checkpoints
- DNA Metabolism when in relation to repair and recombination
Several key therapeutic targets in the DDR landscape are also included within the search capabilities.
Our DDR Team
Kieran Pinto – DDR Research Analyst
Frank Plowden – Account Manager
What is Beacon?
We are a competitive and research intelligence database solution designed in partnership with pharmaceutical professionals across the world working in targeted therapies to provide accurate, in-depth and real-time drugs and trials data in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements